30 closest matches · ranked by relevance
Enterovirus Infection · Type 1 Diabetes · Prediabetic State
Primary: Number of Participants With the Appearance of Type 1 Diabetes Associated Auto-antibodies in Serum — 17; 2 Participants
Enterovirus · Rhinovirus
Primary: Time From First Dose to Symptom Response Over 21 Days of Follow up Based Upon the FLU-PRO Instrument (Novel Endpoint) — 122.5; 137.1 hours — p=0.4009
Viral Intestinal Infection
Primary: Average Diarrhea Duration. — 43.4; 54.7 hours — p=0.004
Enterovirus Infection
Primary: Number of Participants Experiencing Solicited Adverse Events (AEs) Through 48 Hours Post-infusion — 7; 4; 3; 3 Participants
Asthma · Allergic Rhinitis
Primary: Change in Symptom Scores Induced by the Rhinovirus Using Jackson Criteria Including Nasal Congestion, Drainage, Cough, Wheezing — 5.0; 4.2; 2.8 score on a scale
Common Cold
Primary: Interleukin-8 (IL-8) — 133; 122 pg/ml
Asthma
Primary: Airway Symptom Scores Experienced by Subjects During the 1st 4 Days of the Infection — 8.72; 2.77 units on a scale — p=0.049
Healthy Volunteers
Primary: Virus Infection — 8; 18 Participants
Norovirus Infection
Primary: Frequency of Norovirus Gastroenteritis (NVG) — 5; 4 Participants
Adenovirus Infection
Primary: Number of Participants With All-Cause Mortality — 9; 27; 8 Participants
Gastroenteritis Norovirus
Primary: The Occurrence of Norovirus-associated Illness in Secretor Positive Participants Through Day 4 After Challenge. — 3; 2; 7; 0 Participants
Influenza
Primary: Viral Confirmation — 6; 0 Participants
Infectious Mononucleosis
Primary: Number of Participants With Improvement in Clinical Symptoms and Reductions in Viral Burden From Baseline — 12; 11 participants
Venezuelan Equine Encephalitis · Western Equine Encephalitis · Eastern Equine Encephalitis
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 4; 2; 0; 1 Participants
Upper Respiratory Infection · Common Cold
Primary: Local Leukotriene Levels — 440; 368; 440; 619 pg/ml
Norovirus Infections
Primary: Number of Participants Who Experienced Norovirus Gastroenteritis (NVG) — 34; 37 Participants
Rotavirus Infection
Primary: Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the WC3 IgA Assay — 186; 182; 175; 191 participants
Healthy Volunteers
Primary: Number of Participants With Colds With at Least Moderate Intensity — 4; 2; 7; 0 Participants
Asthma
Primary: Airway Symptom Scores Experienced by Participants During the First 4 Days of the Acute Infection. — 4.0; 3.3 units on a scale — p=0.59
Healthy Volunteers
Primary: Number of Participants With Moderate or Severe Acute Gastroenteritis (AGE) Occurring for >7 Days After Dosing Due to GI.1 or GII.4 Norovirus Strains (Excluding…
Bronchiolitis
Primary: Duration of Hospital Stay — 3.9; 2.1 days
Common Cold
Primary: Number of Participants With Rhinovirus-associated Illness Episodes — 63; 60 Participants
Gastroenteritis · Dehydration
Primary: Estimating the Incidence of Rotavirus Gastroenteritis Associated Hospitalization in Children < 5 Years of Age — 428 Participants
Dengue
Primary: Number of Participants With Solicited Injection Site Adverse Events — 1; 0 Participants
Asthma
Primary: Total Number of Asthma Exacerbations Reported During the Treatment Period — 24; 25 Number of asthma exacerbations — p=0.928
Rotavirus Infections · Gastroenteritis · Diarrhea
Primary: Matched VE Participants — 26; 22; 16; 1 participants
Short Bowel Syndrome
Primary: Safety and Tolerability of the Oral RotaTeq® Vaccine — 18; 3 Individual Adverse Events
Infection · Achlorhydria
Primary: Development of Diarrhea — 5; 6 participants
Vibrio Infections
Primary: Number of Participants With Diagnosed Non-cholerae or Non-O1/O139 Vibrio Infection — 20; 7; 2; 18 Participants
Respiratory Syncytial Virus Infections
Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 17; 9; 3; 1 Participants